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Abstract
Background: Traumatic brain injury (TBI) sets in motion cascades of biochemical changes that result in delayed cell death
and altered neuronal architecture. Studies have demonstrated that inhibition of glycogen synthase kinase-3 (GSK-3)
effectively reduces apoptosis following a number of stimuli. The Wnt family of proteins, and growth factors are two major
factors that regulate GSK-3 activity. In the absence of stimuli, GSK-3 is constitutively active and is complexed with Axin,
adenomatous polyposis coli (APC), and casein kinase Ia (CK1a) and phosphorylates ß-Catenin leading to its degradation.
Binding of Wnt to Frizzled receptors causes the translocation of GSK-3 to the plasma membrane, where it phosphorylates
and inactivates the Frizzled co-receptor lipoprotein-related protein 6 (LRP6). Furthermore, the translocation of GSK-3
reduces ß-Catenin phosphorylation and degradation, leading to ß-Catenin accumulation and gene expression. Growth
factors activate Akt, which in turn inhibits GSK-3 activity by direct phosphorylation, leading to a reduction in apoptosis.
Methodology/Principal Findings: Using a rodent model, we found that TBI caused a rapid, but transient, increase in LRP6
phosphorylation that is followed by a modest decrease in ß-Catenin phosphorylation. Phospho-GSK-3b immunoreactivity
was found to increase three days post injury, a time point at which increased Akt activity following TBI has been observed.
Lithium influences several neurochemical cascades, including inhibiting GSK-3. When the efficacy of daily lithium was
assessed, reduced hippocampal neuronal cell loss and learning and memory improvements were observed. These
influences were partially mimicked by administration of the GSK-3-selective inhibitor SB-216763, as this drug resulted in
improved motor function, but only a modest improvement in memory retention and no overt neuroprotection.
Conclusion/Significance: Taken together, our findings suggest that selective inhibition of GSK-3 may offer partial cognitive
improvement. As a broad spectrum inhibitor of GSK-3, lithium offers neuroprotection and robust cognitive improvement,
supporting its clinical testing as a treatment for TBI.
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Introduction
Both clinical and experimental studies have shown that the
pathophysiology of traumatic brain injury (TBI) is complex and
involves both primary and secondary injuries. Primary pathologies
develop extremely rapidly after the traumatic event, and are
typically not amenable to pharmacological interventions. In
addition to causing immediate physical damage to the brain, the
primary injury sets in motion cascades of molecular, cellular,
genomic and metabolic processes that result in secondary injury
[1,2]. Secondary injury encompasses a number of pathological
processes such as neuronal cell death and changes in neuronal
architecture that can continue to evolve over time [3–6]. The
hippocampus, a structure critically involved in learning and
memory, is highly vulnerable to insults to the brain. Studies have
shown that apoptotic loss of hippocampal neurons continues for
days-to-weeks after the initial injury [7,8], an effect thought to
contribute to the learning and memory impairments observed
following experimental TBI and in persons with brain trauma.
Glycogen synthase kinase3 (GSK-3) was originally identified as
a regulator of glycogen metabolism. Its role has been expanded to
include regulation of protein synthesis, cell proliferation, cell
differentiation, microtubule dynamics, cell motility and apoptosis
[9]. GSK-3 activity has been linked to neuronal death triggered by
a number of stimuli such as prion proteins, p53-induced apoptosis
and amyloid-beta toxicity [10–12]. Consistent with a role of GSK-
3 activity in apoptosis, selective small molecular inhibitors of GSK-
3b protect cells in response to these and other pro-apoptotic
stimuli. Wnt and Akt (also called protein kinase B) are two major
signaling pathways that have been shown to regulate GSK-3
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24648activity via distinct mechanisms [13]. In most cells, GSK-3 exists
in a constitutively active form as a part of a protein complex
consisting of APC (adenomatous polyposis coli), axin, and casein
kinase Ia that phosphorylates b-Catenin leading to its degradation
(Figure 1A). Binding of Wnt to the Frizzled-LRP6 (lipoprotein-
related protein 6) receptor complex causes translocation of GSK-3
to the plasma membrane, away from its cytoplasmic substrates,
where it binds to and phosphorylates LRP6 (Figure 1B) [14]. This
leads to reduced phosphorylation of ß-Catenin and decreased
proteosomal degradation. In addition, GSK-3 activity can be
regulated by phosphorylation in response to growth factor binding
via Akt (Figure 1C). This phosphorylation and inactivation of
GSK-3 is thought to play a role in the anti-apoptotic properties of
Akt activation [15]. Although increases in Akt activity have been
observed following TBI, this appears to be insufficient to prevent
TBI-induced apoptotic cell death. We therefore hypothesized that
augmentation of GSK-3 inhibition post TBI would attenuate cell
death and improve neurocognitive outcome in brain injured
animals.
In the present study, we examined the consequences of TBI on
GSK-3 activity and post-TBI administration of GSK-3 inhibitors
on neurocognitive outcome. Treatment of injured animals with
lithium, a multi-target drug that inhibits GSK-3, offered significant
neuroprotection and improved learning and memory in brain
injured animals. However, the GSK-3-selective small molecule
inhibitor SB-216763 resulted in improved motor function, but
only modest cognitive enhancement that occurred in the absence
of visible neuroprotection.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Animal Care
and Use Committee of The University of Texas Health Science
Center at Houston (protocol# AWC-08-046),and were conducted
in accordance with the recommendations provided in the Guide for
the Care and Use of Laboratory Animals. Protocols were designed to
minimize pain and discomfort during the injury procedure and
recovery period.
Materials
Male Sprague-Dawley rats (275–300 g) were purchased from
Charles River Laboratories (Wilmington, MA). Lithium chloride
and SB-216763 was purchased from Sigma Aldrich (St. Louis,
MO) and Tocris Bioscience (Ellisville, MO), respectively. Anti-
bodies to phospho ß-Catenin (Ser
33/37), total ß-Catenin, phospho
GSK-3b (Ser
9), total GSK-3b, phospho-Erk1/2 (Thr
202/Tyr
204,
Thr
185/Tyr
187), total Erk1/2antibodies, phospho-Akt (Ser
473),
total Akt, phospho-LRP6 (Ser
1490), and total LRP6 were
purchased from Cell Signaling Technology (Danvers, MA).
Antibodies to NeuN were obtained from Millipore (Billerica, MA).
Production of traumatic brain injury
All experimental procedures were approved by the Institutional
Animal Care and Use Committee and were conducted in
accordance with the recommendations provided in the Guide for
the Care and Use of Laboratory Animals. Protocols were designed to
minimize pain and discomfort during the injury procedure and
recovery period. An electromagnet-driven controlled cortical
impact (CCI) device was used to cause brain injury as previously
described [16–18]. Briefly, animals were anesthetized using 5%
isofluorane with a 1:1 O2/N2O mixture, mounted a stereotaxic
frame, and a midline incision was made. Bilateral 6-mm
craniectomies were produced midway between the bregma and
lambda with the medial edges of the craniectomies 1-mm lateral to
the midline. Rats received a single impact (2.7 mm deformation)
on the right parietal lobe with an impact velocity of 6 meters/sec.
Core body temperature was maintained at 37-38uC by use of a
heating pad. The animals were given time to recuperate in a
warming chamber before being returned to their home cages.
Animals were weighed daily after the injury for the first 3 days,
then weekly thereafter.
Drug preparation and administration
Lithium chloride was dissolved in sterile saline to a final
concentration of 25 mg/ml. For testing the influence of lithium
chloride on cognitive function following TBI, animals were injured
then injected (s.cu.) with 0.5 ml (1 mEq/kg lithium) or an equal
volume of vehicle 30 minutes post-injury, and every 24 hours
thereafter for the first 5 days post-injury (n=10/group). For
biochemical analysis, naı ¨ve rats were given an s.cu. injection of
lithium (0.1, 0.25, 0.5 or 1 mEq/kg) or vehicle once a day for 5
continuous days (n=3/dose). Three hrs after the last injection, rats
were killed by decapitation and hippocampi removed for the
preparation of protein extracts. For single dose studies, 1.0 mEq/
Kg lithium was injected, and the animals killed 3 hr later. The
selective GSK-3b inhibitor, SB-216763, was dissolved in DMSO
to a stock concentration of 8.33 mg/mL and further diluted in
60% PEG400 and 30% distilled water for a final concentration of
0.83 mg/mL. For testing the influence of GSK-3b inhibition on
cognitive function following TBI, animals were i.p. injected with
5 mg/kg SB-216763 or an equal volume of vehicle 30 min
following injury and every 24 hours thereafter for the first 5 days
after injury (n=10/group). For biochemical analysis, uninjured
rats were given a single i.p. injection with SB-216763 (2.5 or
5 mg/kg) and killed 1 hr later (n=3/dose).
Sample Preparation
Hippocampal tissues were quickly removed while submerged in
ice cold artificial cerebral spinal fluid (10 mM HEPES pH 7.2,
1.3 mM NaH2PO4, 3 mM KCl, 124 mM NaCl, 10 mM dextrose,
26 mM NaHCO3 and 2 mM MgCl2) containing phosphatase
inhibitors (2 mM sodium fluoride, 2 mM sodium molybdate and
1 mM sodium orthovanadate). Tissues were homogenized (20
strokes) in 10 volumes of a buffer containing 10 mM Tris pH 7.4,
1 mM EGTA, 1 mM EDTA, 0.5 mM DTT, phosphatase
inhibitors (0.1 mM okadaic acid and 1 mM sodium orthovanadate)
and protease inhibitors (1 mM PMSF and 10 mg/ml leupeptin)
using a motorized teflon-glass homogenizer. The samples were
immediately aliquoted and frozen at 280uC.
Western Blotting
Hippocampal tissue extracts were sonicated (5 pulses of 1
second each) using a Sonics Vibracell sonicator (Sonics &
Materials, Inc., Newtown, CT) and a 0.4 mm diameter probe.
The amount of protein in each sample was determined by a
Bradford assay using bovine serum albumin (BSA) as the standard.
Samples were denatured at 95uC for three minutes in 1x NuPage
SDS sample buffer (Invitrogen, Carlsbad, Calif.). Equal amounts
of protein were loaded, electrophoresed, and transferred to
Immobilon-P membranes (Millipore, Billerica, MA) using the
NOVEX X-Cell II system (Invitrogen, Burlingame, CA) and the
buffers provided by the vendor. Membranes were blocked
overnight in 5%BSA in TBST, followed by a three-hour
incubation in primary antibodies (0.1–0.5 mg/ml in TBST
containing 2% BSA) at room temperature. Membranes were then
washed in TBST and incubated at room temperature with alkaline
phosphatase (AP)-conjugated secondary antibodies for one hour as
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24648Figure 1. TBI alters the regulation of GSK-3. A) Schematic diagram showing the GSK-3 cascade. In the absence of Wnt signaling, GSK-3
complexes with APC, Axin, and casein kinase 1a (CK1a) and phosphorylates ß-Catenin (ß-cat) leading to its ubiquitination (Ub) and degradation.
B) Upon Wnt binding to the Frizzled-LRP6 receptors, GSK-3 is translocated to the membrane via binding of Disheveled (Dsh) where it can
phosphorylate LRP6, and allow for ß-Catenin accumulation and gene expression (via interaction with LEF/TCF transcription factors). C) Growth factor
binding can result in Akt-mediated phosphorylation and inactivation of GSK-3. Rats (n=5/time point) were subjected to TBI and hippocampi
removed at various time points for western blot analysis. Representative images of western blots for D) phospho- and total LRP6, F) phospho- and
total GSK-3ß, and H) phospho- and total ß-Catenin are shown. E) Summary data shows that TBI causes a transient increase in the phosphorylation of
LRP6 on Ser
1490. G) The phosphorylation of GSK-3ß on Ser
9 is increased in a delayed manner, at a time point consistent with its phosphorylation by
Akt. I) ß-Catenin phosphorylation was decreased at time points consistent with GSK-3 translocation to LRP6, but not as a result of GSK-3
phosphorylation. No change in ß-Catenin accumulation was observed. Data are presented as the mean 6 SEM. *, P,0.05 by one-way ANOVA
compared to sham animals.
doi:10.1371/journal.pone.0024648.g001
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CA). Following extensive washing, immunoreactivity was detected
using a chemiluminescence system and quantified using Image J
(freely available through NIH).
Assessment of motor function
All behavioral tests were conducted by an experimenter blind to
the treatment groups. A vestibulomotor (beam balance) and a
motor skill task (paw placement) were used to determine animals’
motor performance on days 1–4 post-injury. For beam balance,
rats were pre-assessed by placing them on a narrow wooden beam
(1.5 cm wide) and measuring the duration they remained on the
beam for up to 60 seconds. Animals were given repeated training
until capable of balancing on the beam for the entire 60 sec period
for 3 consecutive trials. Following injury, animals were given three
daily trials during which the length of time spent on the beam was
recorded. Paw placement was evaluated by placing the animal on
a wire grid (opening size of 262 cm) and counting the number of
foot faults out of a total of 50 steps. A foot fault was defined as
when a front paw misses and appears below the plane of the grid.
Paw placement was repeated three times to give an average daily
score.
Assessment of cognitive function
Rats were tested for their cognitive performance using the
standard hidden platform version of the Morris water maze
[17,19–21]. All animals had recovered from the TBI-associated
motor dysfunction prior to performing the cognitive testing.
Animals were given 4 consecutive training trials per day with an
inter-trial interval (iti) of 4min. If the animal failed to locate the
platform within 60 sec on any given trial, it was led there by the
experimenter. Thirty minutes after the last daily training trial,
animals were given a probe trial to measure quadrant preference
and platform localization. Twenty-four hours following the last
day of training, animals were again tested in a probe trial to
measure quadrant preference and platform localization. Move-
ment within the maze was monitored using a video camera linked
to tracking software (Ethovision, Noldus Information Technology,
Leesbury, VA, USA).
Contusion volume measurement
Following the completion of the behavioral studies, approxi-
mately 28 days following the injury, animals (n=10/group) were
deeply anesthetized with sodium pentobarbital (100 mg/kg) and
transcardially perfused with phosphate buffered saline (PBS)
followed by 4% paraformaldehyde. Brains were removed, post-
fixed overnight in perfusant, then cryoprotected in a 30% sucrose
solution. Cortical tissue loss was estimated essentially as described
previously [22], by experimenters kept blind with respect to the
treatment groups. In brief, cryosections (40 mm thickness)
spanning the rostral-caudal extent of the injured cortex were
selected and stained with cresyl violet by an experimenter given
only the animal’s identifier code. Images of the resultant slides
were then used for tissue loss measurement by a second
experimenter. The area of cortical tissue loss for each section
was carefully outlined using Adobe Illustrator, with the area of the
resultant outlines quantified by Image J, from the National
Institutes of Health. Contusion volume was calculated using the
equation A1(0.5X1)+A2(0.5X1 +0.5X2)+An-1(0.5Xn-1 +0.5Xn)+
An(0.5Xn) where A is the area (mm
2) of the contusion for each
slice, and X is the distance (mm) between two sequential slices.
Once the contusion volume had been calculated for each animal,
the blind code was broken and group differences assessed.
Immunohistochemistry
For post-TBI histological evaluation, tissue sections generated
for the measurement of cortical contusion volume were used for
immunohistochemistry. Free-floating slices were incubated over-
night in primary antibody (0.5–1.0 mg/ml) in TBS containing 2%
BSA and 2.5% normal goat serum. After extensive washing,
immunoreactivity was detected using species-specific secondary
antibodies coupled to Alexafluors. These fluorescently-labeled
tissue sections were evaluated by a blind observer to identify any
potential differences between the treatment groups. As visible
neuroprotection was detected following lithium administration,
stereological cell counts were carried out. For cell counts, NeuN
immunostaining was performed using a colorimetric detection
system consisting of a secondary antibody conjugated to
horseradish-peroxidase and diaminobenzadine (DAB) as the
chromagen. This was done to avoid the photobleaching often
associated with high magnification imaging of fluorescent
immunohistochemistry.
Stereology
A blind counting methodology was employed for determination
of NeuN positive cells in the CA3 layer of the ipsilateral
hippocampus in lithium chloride- and vehicle-treated animals
(n=5/group). Every tenth section through the ipsilateral dorsal
hippocampus was processed for NeuN immunoreactivity using
colorimetric detection as described above. NeuN positive cells
within the CA3 subfield were counted using the optical dissector
technique using Stereo Investigator (MicroBrightField Bioscience,
Williston, VT) [23]. The CA3 subfield was differentiated from the
CA2 by the density of cells within these layers. As there is no
morphological distinction between the CA3 and CA4 subfields
using NeuN staining, these subfields were divided by dropping a
vertical line from the lateral edge of the inner blade of the dentate
gyrus. Cells in the outermost planes of focus (5 mm) were omitted
to avoid counting cell caps. The number of NeuN-labeled cells in
approximately twenty, computer chosen areas within the CA3 cell
layer was scored for each section. The counting frame was
1086108 mm. The size of the counting frame, and the number of
grid sections was determined based on preliminary cell counts.
The number of NeuN labeled cells/mm
3 for each section was
obtained from the estimated cells divided by the contour volume.
The number of cells/mm
3 for each animal was calculated as the
average of the number of cells/mm
3 from each section examined.
Statistical Analysis
For evaluation of behavioral data, repeated measures analyses
of variance (two-way or one-way as appropriate) and t-tests were
utilized to determine statistical differences. A Holm-Sidak method
for multiple comparisons post-hoc test was used to determine data
points with significant differences. Dose response western data
were evaluated using a one-way ANOVA followed by a Dunnet’s
post-hoc test. For data that did not pass a Shapiro-Wilk normality
test, appropriate non-parametric analysis was performed. Data
were considered significant at p#0.05 and presented as Mean 6
Standard Error of the Mean (S.E.M.).
Results
TBI causes transient inhibition of the GSK-3 pathway
To determine the influence of TBI on GSK-3 activity, western
blots were performed to examine the phosphorylation of LRP6,
GSK-3ß, and ß-Catenin in hippocampal extracts prepared at
various time points following injury (n=5/time point). Figure 1D
shows images of representative westerns illustrating the phosphor-
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1490. This site has been shown
to be phosphorylated in response to GSK-3 translocation to the
LRP6 signalosome [14]. The summary data presented in Figure 1E
show that the phosphorylation of LRP6 is significantly increased
by 30 min post-injury (one-way ANOVA: F(5,24)=4.297;
P=0.006). The total levels of LRP6 did not significantly change
at any of the time points examined (one-way ANOVA:
F(5,24)=0.587; P=0.710). As described above, GSK-3 is also
inhibited following phosphorylation by Akt. Previous studies have
reported that cortical impact injury results in increased Akt
phosphorylation (on Thr
308) and activity 3-day post-injury [24].
We therefore examined if GSK-3 phosphorylation is enhanced 3-
day post-CCI. The representative western blots and the summary
data shown in Figures 1F and 1G demonstrate that the
phosphorylation of Ser
9 of GSK-3ß increases after injury, reaching
significance by the 3-day time point (one-way ANOVA: pGSK-3
F(5,24)=7.335; p,0.001). This is consistent with a previous study
which showed that GSK-3 phosphorylation is increased in the
hippocampus for at least 24 hr after a weight drop model of TBI
[25]. No change in the total levels of GSK-3ß was detected
(Figure 1G; one-way ANOVA: GSK-3 F(5,24)=0.622; p=0.684).
Upon inactivation by either the Wnt-LRP6 or Akt cascades,
GSK-3-mediated phosphorylation of ß-Catenin on Ser
33/37 is
reduced, leading to its nuclear accumulation and enhanced gene
expression. To assess if the TBI-associated decreases in GSK-3
activity are associated with changes in ß-Catenin phosphorylation
and levels, western blots were again carried out. Figure 1H shows
representative western blots illustrating phospho-ß-Catenin immu-
noreactivity at different time points following injury. The summary
data in Figure 1I demonstrates that TBI causes a significant, but
transient, decrease in the phosphorylation of Ser
33/37 of ß-Catenin
acutely following injury (one-way ANOVA: F(5,24)=4.948;
p=0.003). Although a significant decrease in ß-Catenin phosphor-
ylation was observed by 3 hr post-injury, no concurrent increase in
the total levels of this protein was observed (one-way ANOVA:
F(5,24)=1.208; p=0.336). No changes in either the phosphorylation
or total levels of ß-Catenin were observed at the time point at which
GSK-3ß phosphorylation was observed.
Lithium treatment improves hippocampal function and
reduces neuronal loss following TBI
Inhibition of GSK-3 has been shown to reduce neuronal death
triggered by a number of stimuli [13]. Although GSK-3 activity
appears to be modulated by both receptor- and Akt-mediated
mechanisms following brain injury, these effects were transient and
apparently insufficient to prevent TBI-associated hippocampal cell
death. In order to determine the consequences of further
inhibition of the GSK-3 pathway, post-injury administration of
lithium was tested. A number of previous studies have shown that
many of the protective effects of lithium are mediated by its
influence on the GSK-3 cascade [26], although several other
targets of its action have been reported. To confirm that systemic
administration of lithium can inhibit the GSK-3 cascade in the
brain, animals were s.cu. injected with 1 mEq/kg lithium (n=3) or
saline (n=5) for five consecutive days. This dose was chosen based
on a previous study that demonstrated that delayed administration
of 1mEq lithium after cerebral ischemia reduced cortical infarct
volume and facilitated neurological recovery [27]. In addition, we
also tested the influence of lower doses of lithium, namely 0.10,
0.25, and 0.50 mEq/Kg (n=3/dose). Three hours following the
last injection, hippocampal protein extracts were prepared for
western blots. Figure 2A shows representative western blots of
phosphorylated (Ser9) GSK-3ß following different concentrations
of lithium. Since the evaluation of the 1.0 mEq/Kg dose, and the
dose-response study (0.1, 0.25, and 0.5 mEq/Kg) were carried out
at two different times, an independent vehicle group was used for
each analysis. The summary data show that when normalized
across experiments, all doses tested effectively increased the
phosphorylation of GSK-3ß (one–way ANOVA: F(4,12)=5.326,
p=0.011). No significant difference was detected in the total levels
of GSK-3ß (one–way ANOVA: F(4,12)=1.770, p=0.200)
(Figure 2B). Although all doses increased GSK-3 phosphorylation,
significant accumulation of ß-Catenin was only observed at the
high doses (one-way ANOVA: F(4,12)=49.283, p,0.001), with
maximal accumulation observed at 1.0 mEq lithium (Figure 2C).
Since maximal ß-Catenin accumulation was observed after 5 daily
injections of the 1.0 mEq dose, we questioned if a single injection
was sufficient to elicit this effect. To test this, animals received a
single injection of either 1.0 mEq/Kg lithium or an equal volume
of vehicle and killed 3 hr later. The western blot results shown in
Figure 2D demonstrate that a single dose of lithium had no
significant effect on GSK-3 phosphorylation (Student’s t-test:
0.956), total GSK-3 levels (Student’s t-test: 0.130) or ß-Catenin
levels (Student’s t-test: 0.587). Based on these results, we tested the
consequences of daily post-injury administration of 1.0 mEq
lithium for the first 5 days after injury using a series of behavioral
and cognitive tasks.
The influence of post-injury lithium injection on vestibulomotor
and motor function was tested on days 1–4 post-injury using the
beam balance and foot fault tasks, respectively (Figure 3A). Rats
were injured, and then injected s.cu. with 1mEq/kg (n=10) or
vehicle (n=10) 30 min after the injury. Drug administration was
continued every 24 hr for the first 5 days of injury. Figure 3B
shows that post-injury administration of lithium did not signifi-
cantly improve beam balance performance compared to simulta-
neously tested vehicle controls (repeated measures two-way
ANOVA: F(1,18)=3.267, p=0.087). In addition, neither ipsilateral
(repeated measures two-way ANOVA: F(1,18)=2.033, p=0.170;
Figure 3C) nor contralateral (repeated measures two-way
ANOVA: F(1,18)=1.589, p=0.222; Figure 3D) foot faults were
significantly different between the two groups. At the dose tested,
however, lithium significantly exacerbated post-injury weight loss
(two-way repeated measures ANOVA: F(1,18)=14.324, p=0.001).
All animals had normal vestibulomotor and motor function by day
7 post-injury (data not shown), and had returned to their pre-
injury weight.
When these animals were tested for their ability to perform the
Morris water maze task (beginning on day 14 post-injury), the rats
treated with lithium had learning curves that were significantly
different from their vehicle-injected counterparts (significant
interaction by repeated measures two-way ANOVA:
F(9,162)=4.082, p,0.001; Figure 4A). When tested in a probe
trial 24 hr following training, the lithium-treated injured animals
crossed the original platform location significantly faster (vehicle:
48.5266.17 sec; lithium chloride: 26.5765.67 sec, p=0.017) and
more often (vehicle: 0.3060.15 crosses; lithium chloride:
2.0060.49 crosses, p=0.003) than vehicle-infused animals,
suggesting an improved memory for the platform location
(Figure 4B). In support of this conclusion, the lithium chloride-
injected rats demonstrated a preference for the quadrant in which
the platform was located (repeated measures one-way ANOVA:
F(3,27)=11.50, p,0.001) while the saline-injected controls did not
(repeated measures one-way ANOVA: F(3,27)=0.62, p=0.619)
(Figure 4C). Comparison across groups revealed a significant
interaction between treatment and quadrant (repeated measures
two-way ANOVA: F(3,54)=6.58, p,0.001) with a significant
difference in the time each group spent searching in the target
quadrant (quadrant I). Short-term memory was found to be
Glycogen Synthase Kinase-3 and TBI
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latency to cross the original platform location (Student’s t-test
p=0.034) and more number of platform crossings (Student’s t-test
p=0.004) (Figure 4D) in a probe trial given 30 min post-training.
The improved water maze performance we observed as a result
of lithium treatment suggests that this drug may offer neuronal
protection to hippocampal neurons after TBI. When the brains of
the animals used for behavioral testing were examined for
hippocampal neuron loss, an apparent preservation of ipsilateral
CA3 pyramidal neurons (Figures 5A) was observed. To quantify
the number of ipsilateral CA3 neurons, sections spanning the
dorsal hippocampus from representative vehicle (n=5)- and
lithium (n=5)-treated animals were immunoreacted for NeuN.
Immunoreactivity was detected using a horseradish peroxidase-
coupled secondary antibody, and then visualized using diamino-
benzidine (Figure 5B). Stereological cell counts of CA3 pyramidal
neurons were performed using the optical dissector probe of Stereo
Investigator. These counts revealed that animals treated with lithium
had significantly more ipsilateral CA3 pyramidal neurons than
those counted in vehicle-injected animals (Figure 5C). Cortical
contusion volume, however, was not significantly different between
the two groups (Figure 5D).
The GSK-3 inhibitor SB-216763 improves motor function
following TBI
As our results with lithium suggested that GSK-3 inhibition may
offer neuroprotection, we next tested if a GSK-3-specific inhibitor
could mimic the influences of lithium. SB-216763 has been shown
to be a potent inhibitor of GSK-3, while having no significant
influence on the activity of other kinases [26]. To test the efficacy
of the drug, rats were i.p. injected with either 2.5 or 5.0 mg/kg
SB-216763 (n=3/group), euthanized 1 hr later, and the hippo-
campus dissected for the preparation of protein extracts. These
doses were chosen based on previous studies indicating that SB-
216763 can reduce D1 agonist-induced hyperactivity [28].
Representative western blots are shown in Figure 6A. Consistent
Figure 2. Systemic lithium administration inhibits hippocampal GSK-3 activity. A) Representative western blots showing the dose
response of different amounts of lithium (injected daily for 5 days) on GSK-3ß phosphorylation. The summary data shows that all doses of lithium
were found to increase GSK-3 phosphorylation. B) Representative western blots and summary data showing that the different doses of lithium had
no effect on the total levels of GSK-3ß. C) Representative western blots and summary data showing that lithium administration causes a significant
accumulation of ß-Catenin, with maximal levels seen at the 1.0 mEq dose. D) Representative western blots and summary data showing that a single
dose of 1.0 mEq/Kg lithium has no effect on the phosphorylation or total levels of GSK-3ß, nor on ß-Catenin accumulation. Data are presented as the
mean 6 SEM. *, P#0.05 by one-way ANOVA compared to vehicle (0 dose) injected animals. n=3/group.
doi:10.1371/journal.pone.0024648.g002
Figure 3. Post-TBI lithium administration has no effect on
motor function, but exacerbates post-injury weight loss.
A) Schematic of the injection and behavioral testing paradigm. Injured
rats receiving 1 mEq/kg lithium (n=10) performed similarly to vehicle-
injected animals (n=10) when tested for their B) balance beam
performance, and C) ipsilateral and D) contralateral foot faults.
E) Lithium exacerbated post-injury weight loss. Data are presented as
the mean 6 SEM. ?, significant difference by repeated measures two-
way ANOVA. *, P#0.05.
doi:10.1371/journal.pone.0024648.g003
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the phosphorylation of GSK-3b on Ser
9 (one-way ANOVA:
F(2,6)=8.833, p=0.016), suggesting decreased GSK-3 activity.
Associated with this was a significant decrease in the phosphor-
ylation of LRP6 on Ser
1490 (one-way ANOVA: F(2,6)=5.891,
p=0.038; Figure 6C) and a trend towards decreased ß-Catenin
phosphorylation on Ser
33/37 (one-way ANOVA: F(2,6)=4.697,
p=0.059; Figure 2D). No significant influence of SB-216763 was
observed on the phosphorylation/activity of Akt (one-way
ANOVA: F(2,6)=0.381, p=0.698; Figure 6E) or ERK1/2 (one-
way ANOVA: F(2,6)=0.865, p=0.468; Figure 2F), nor on the total
levels of any of the targets interrogated.
In order to determine the influence of SB-216763 on TBI
outcome, rats were injured, then i.p. injected 30 minutes later with
either 5.0 mg/kg SB-216763 or vehicle (n=10/group). Rats
continued to receive daily injections for the first 5 days after injury
during which time they were tested for their vestibulomotor and
motor performances (Figure 7A). Drug administration was
continued for 5 days since previous studies have reported that
apoptosis continues for days after TBI [29]. While SB-216763
injected animals did not perform any differently on the balance
beam task compared to vehicle-injected control animals (repeated
measures two-way ANOVA: F(1,18)=0.039, p=0.846 (Figure 7B),
they did show significantly less ipsilateral (Figure 7C; repeated
measures two-way ANOVA: F(1,18)=4.74, p=0.040) and contra-
lateral (Figure 3D; repeated measures two-way ANOVA:
F(1,18)=9.97, p=0.004) foot faults as compared to their vehicle-
injected counterparts. SB-216763 treatment did not have any
significant influence on post-injury weight loss (Figure 7E;
repeated measures two-way ANOVA: F(1,18)=0.282, p=0.602).
All animals had normal vestibulomotor and motor function by day
7 post-injury (data not shown).
When evaluated for their performance in the standard hidden
platform version of the Morris water maze task (beginning 14 days
post-injury), no difference in learning was detected between
injured rats treated with 5.0 mg/kg SB-216763 and those treated
with vehicle (Figure 8A; repeated measures two-way ANOVA:
F(1,18)=1.639, p=0.217). Similarly, when a probe trial was given
24 hr after the completion of training, no differences were seen in
the latency to cross (vehicle: 36.6867.24 sec; SB-216763:
42.8166.88 sec, p=0.725) or the number of platform crossings
(vehicle: 1.3060.40 crosses; SB-216763: 0.9060.28 crosses,
p=0.50) between the two groups (Figure 8B). Figure 8C shows
that while both the vehicle (one-way repeated measures ANOVA:
F(3,27)=3.186, p=0.040) and SB-216763 (one-way repeated
measures ANOVA: F(3,27)=4.019, p=0.017) treated groups
displayed significant preference for the target quadrant (I) relative
to the starting quadrant (III), there was no significant difference
between the two groups in their quadrant preferences (two-way
repeated measures ANOVA: F(1,18)=0.971, p=0.338). Interest-
ingly, when a short term memory test was given at 30 minutes
following training, SB-216763 injected animals crossed the
platform location significantly more than the vehicle-injected
controls (vehicle: 1.1060.35 crosses;SB-216763: 2.3060.42 cross-
es, p=0.042; Figure 8D). No difference in latency (Figure 8D) nor
quadrant preference (data not shown) was observed between the
two groups during the short-term memory probe trial. Consistent
with the lack of improvement in the water maze, histological
Figure 4. Post-injury administration of lithium chloride im-
proves cognitive function following TBI. Rats treated with 1 mEq/
kg lithium (n=10) had improved spatial learning and memory as
indicated by A) decreased latencies to the platform during training (?,
significant difference by repeated measures two-way ANOVA), and
B) decreased latency to the first platform crossing and increased
number of platform crossings during a probe trial given 24 hr after
training (*, p#0.05 by Student’s t-test). C) Animals receiving lithium
spent significantly longer time in the target quadrant (I) compared to
the other quadrants (II, III, IV), suggesting improved localization (*,
p#0.05 by repeated measures one-way ANOVA). D) A probe trial given
30 min after training showed that the lithium-infused animals also had
significantly shorter latencies and more crossings of the platform
location compared to vehicle-infused animals (*, p#0.05 by Student’s t-
test). Veh: vehicle; Li: lithium. Data are presented as the mean 6 SEM.
doi:10.1371/journal.pone.0024648.g004
Figure 5. Post-injury administration of lithium reduces hippo-
campal neuronal cell loss. A) Representative photomicrographs of
NeuN immunoreactivity from the dorsal, ipsilateral hippocampi of a
vehicle- and a lithium-treated animal. Scale bar =500 mm. DG: dentate
gyrus. The outlined area indicates the field in which the cell counts were
carried out. B) High-magnification image showing NeuN immunoreac-
tivity within the CA3 subfield from a vehicle- and a lithium-injected,
injured animal. Scale bar =200 mm. Lithium treatment C) significantly
reduced CA3 neuronal loss, but not D) cortical contusion volume after
TBI. *, p#0.05 by Student’s t-test. Veh: vehicle; Li: lithium. Data are
presented as the mean 6 SEM.
doi:10.1371/journal.pone.0024648.g005
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hippocampal neuronal loss (as indicated using NeuN immunore-
activity) between injured animals treated with vehicle and those
given SB-216763 (Figure 8E), with both groups having demon-
strable neuron loss in the dentate gyrus (DG) and CA3 subfields.
Neither ipsilateral (vehicle: 28.3062.98 mm
3 vs. SB-216763:
28.2962.98 mm
3; Student’s t-test p=0.99) nor contralateral
(vehicle: 14.4862.81 mm
3 vs. SB-216763: 12.3962.61 mm
3;
Student’s t-test p=0.59) cortical tissue loss was different between
the two groups.
Discussion
Using a rodent model of TBI, we examined if post-injury
inhibition of GSK-3 activity is neuroprotective, and if this
neuroprotection is associated with improved motor and cognitive
outcomes. Our findings show that daily, post-injury administration
of the GSK-3 inhibitor lithium for five days significantly improved
hippocampal-dependent learning and memory and reduced
hippocampal CA3 neuron loss. In contrast, the GSK-3-selective
inhibitor SB-216763 improved motor function, but did not
provide overt neuroprotection and only modestly improved
learning and memory.
One of the most studied mechanisms of GSK-3 regulation is the
canonical Wnt pathway. In the absence of Wnt, GSK-3 exists as a
part of a destruction complex consisting of the scaffold protein
Axin, the tumor suppressor APC, and casein kinase Ia (CKIa) that
binds to, and regulates, ß-Catenin-mediated gene expression [9]
(see Figure 1A). Phosphorylation of ß-Catenin by CKIa and GSK-
3 marks it for proteosomal degradation. Upon Wnt binding to the
Frizzled receptor, GSK-3 is recruited to the plasma membrane
where it can phosphorylate the Frizzled co-receptor LRP6 on five
PPPSP motifs. These phosphorylation events prime the receptor
for subsequent phosphorylation by CKIc [30]. Several studies
have indicated that the phosphorylation of LRP6 is crucial for
reducing ß-Catenin phosphorylation and degradation [14]. When
the phosphorylation of LRP6 was examined in hippocampal
extracts following TBI, we observed a transient, but significant
increase in Ser
1490 phosphorylation, suggesting GSK-3 transloca-
tion. However, as other kinases have also been shown to
phosphorylate LRP6 on Ser
1490, we cannot rule out their
involvement in the increased phosphorylation we observed [14].
Regardless of the mechanism underlying its phosphorylation, it
appears that phosphorylated LRP6 acts, at least in part, to inhibit
GSK-3. Using phosphorylated peptide mimetic of LRP6, it has
been shown that peptides containing the PPPSPxS motif of LRP6
Figure 6. SB-216763 inhibits the GSK-3 pathway. A) Represen-
tative images of western blots for phospho-GSK-3ß, phospho-LRP6,
phospho-ß-Catenin, phospho-Akt, and phospho-ERK in response to i.p.
injection of SB-216763 (2.5 and 5.0 mg/kg) or vehicle (0 mg/kg) (n=3/
group). B) SB-216763 significantly increased the phosphorylation of
GSK-3ß in a dose-dependent manner. The phosphorylation of the GSK-3
substrates C) LRP-6 and D) ß-Catenin, were found to be decreased
following SB-216763 administration. The phosphorylation levels of
E) Akt and F) ERK were unaffected by SB-216763 administration. Data
are presented as the mean 6 SEM. *, P,0.05 by one-way ANOVA.
doi:10.1371/journal.pone.0024648.g006
Figure 7. Post-injury administration of SB-216763 improves
motor function. A) Schematic of the drug injection and behavioral
testing paradigm. Rats (n=10/group) were injected (i.p.) for the first 5
days post-injury with either 5.0 mg/kg SB-216763 or vehicle. SB-216763-
treated rats had B) comparable vestibulomotor deficits, but made
significantly fewer C) ipsilateral and D) contralateral foot faults. E) Body
weight was unaffected by SB-216763 administration. Data are
presented as the mean 6 SEM. {,P ,0.05 by two-way repeated
measures ANOVA.
doi:10.1371/journal.pone.0024648.g007
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signaling after TBI, the enhanced LRP6 phosphorylation we
observed was followed by a significant decrease in GSK-3-
dependent ß-Catenin phosphorylation.
In addition to Wnt signaling, GSK-3 has been shown to be
inhibited by direct phosphorylation by a number of kinases
including protein kinase A (PKA) [33], Akt [34], PKC [35], p90
ribosomal S6 kinase (p90RSK) [36] and p70 ribosomal S6 kinase
(p70S6K) [37]. Our results indicate that TBI causes a delayed
increase in GSK-3ß phosphorylation on Ser
9. Although the kinase
responsible for this phosphorylation has not been identified, the
time point at which we observed the increase (3 days post-injury),
is consistent with that seen for activation of Akt. Using a cortical
impact model of injury, Zhang et al., reported that TBI causes a
delayed phosphorylation of Akt on Thr
308 that occurs 72 hr post-
injury [38]. Although we observed a significant increase in GSK-
3ß phosphorylation, no corresponding decrease in ß-Catenin
phosphorylation was seen at this time point. While the reason for
this is not clear at present, it is possible that the activity of GSK-
3a, which can also phosphorylate ß-Catenin, was unaffected by
TBI [39] and could have maintained ß-Catenin phosphorylation.
Accumulating evidence suggests that GSK-3 may play an
important role in apoptosis with its overexpression inducing, and
its inhibition preventing, apoptosis [9,40,41]. Although we
observed that GSK-3 is negatively regulated as a result of TBI,
the continued presence of neuron death suggests that this
inhibition is not sufficient to protect the hippocampus from TBI-
associated apoptosis [7,8]. As several studies have indicated that
administration of the GSK-3-selective inhibitor SB-216763 can
protect cultured neurons against excitotoxicity and toxin-induced
apoptosis [42–44], and it has been shown to reduce the presence of
pyknotic neurons in a model of Alzheimer’s disease [12], we
questioned if similar benefits could be observed following TBI. In
contrast to our anticipation, animals treated with the selective
GSK-3 inhibitor SB-216763 had comparable hippocampal cell
loss to injured rats treated with vehicle, and only showed a modest
improvement in short-term memory. Our biochemical assessment
of the consequences of SB-216763 demonstrated that the dose
employed in our behavioral studies (5.0 mg/kg) effectively reduced
GSK-3 activity in the hippocampus, and this dose has been used
by other investigators to examine the consequences of GSK-3
inhibition in vivo [28]. While these results suggest that SB-216763
is only partially effective at reducing TBI pathology, it is possible
that a higher concentration of the drug would have been more
effective in reducing TBI-associated behavioral dysfunction.
Since multiple mechanisms contribute to TBI pathophysiology,
it is thought that a drug specific for a single target may not give rise
to meaningful improvements in neurobehavioral outcome. There
is a general consensus among TBI researchers that either a
combination treatment, or a drug that targets multiple TBI-
associated pathological cascades, is likely to be effective as a
treatment [45]. Based on this premise, we tested the efficacy of
lithium, a relatively non-selective inhibitor of GSK-3. Lithium
inhibits GSK-3 both directly [36,46], and indirectly by reducing
the activity of protein phosphatase-1 [47] and by increasing the
phosphorylation of GSK-3 via activation of Akt [48]. Lithium has
been shown to attenuate multiple pathological processes that have
been reported to contribute to TBI pathophysiology such as
apoptosis, oxidative stress, and mitochondrial and endoplasmic
dysfunction. For example, pre-treatment with lithium protects
cultured neurons from glutamate-induced cell death [49,50], and
reduces the oxidative stress associated with neuropeptide S [51].
Bipolar patients on lithium have reduced levels of N-acetyl
aspartate (NAA), a marker for neural injury, and have more gray
matter volume as compared to control patients that are not on
lithium therapy [52–55]. Although many of these neuroprotective
properties of lithium are thought to be due to its influence on
GSK-3 [56], lithium has been demonstrated to alter the activity of
several other pathways. For example, lithium can indirectly block
PKC activity by inhibiting inositol monophosphatase (IMPase)
activity [57], thereby reducing the generation of diacylglycerol and
inositol triphosphate. Nucleotide bisphosphate 39-nucleotidase
(BPntase, also called RnPIP) is noncompetitively inhibited by
lithium [58], whereas lithium has been shown to activate the
ERK/MAPK cascade [59]. Although we observed that lithium
effectively inhibited GSK-3, we cannot rule out the contribution of
these other targets of lithium on the results we observed.
Recently, it has been shown that pretreatment of mice with
lithium prior to brain injury reduces inflammation, prevents TBI-
induced depression, improves spatial learning and memory, and
protects against hippocampal cell loss [25,60]. Consistent with this,
we observed that lithium, when administered post-TBI and
continued for an additional 5 days, significantly improved
hippocampal function as indicated by improved learning and
memory in the Morris water maze task tested days 14–25 post-
Figure 8. Post-injury administration of SB-216763 partially
improves spatial memory, but does not offer neuroprotection.
A) SB-216763-treated rats performed similarly to rats treated with
vehicle in the hidden platform version of the Morris water maze task. No
significant influence of SB-216763 administration was seen in either the
B) latency to the first platform crossing or number of platform
crossings, nor C) quadrant preference in a probe trial given 24 hr
following training. *, P,0.05 by one-way repeated measures ANOVA.
D) When given a probe trial 30 min after training, SB-216763-treated
rats crossed the hidden platform location significantly more times than
did the vehicle treated controls. *, P,0.05 by Student’s t-test.
E) Representative photomicrographs of NeuN immunoreactivity from
the dorsal, ipsilateral hippocampi of a vehicle- and a SB-216763-treated
animal. Data are presented as the mean 6 SEM. DG: dentate gyrus.
Scale bar =500 mm.
doi:10.1371/journal.pone.0024648.g008
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improvements were accompanied by a significant preservation in
CA3 hippocampal neuron numbers. Although studies have shown
that cell death after TBI can continue for weeks-to-months, the
majority of hippocampal cell loss occurs within the first few days
after the injury [8,61,62]. As inhibition of GSK-3 has been shown
to offer neuroprotection in response to several toxic agents, it is
likely that the protection observed was due to a reduction in
hippocampal cell death within the initial 5-day period after injury
(the time frame of lithium administration). However, we can rule
out any lasting neuroprotective effects of lithium treatment that
may have contributed to the behavioral and histological
improvements we observed.
Although oral lithium carbonate is an effective therapy of
treating bipolar disorders, benefit is typically only seen following
prolonged use. This delayed onset of action is in contrast to the
relatively acute effects described herein. While the mechanism
underlying lithium’s effect following TBI is not clear, a few studies
have suggested that mechanistic differences exist between acute
and chronic lithium treatment paradigms. For example, chronic,
but not acute, lithium treatment increases BDNF expression in the
rat hippocampus and temporal cortex [63], and BDNF expression
has been observed following 28days of lithium treatment in
persons with bipolar disorder [64]. In contrast, neuroprotection
can be observed following acute lithium treatment, an effect
thought to be due to a reduction of GSK-3-mediated apoptosis
[65]. While we observed that GSK-3 activity could be inhibited
using an acute administration routine (daily dosing for 5 days post-
injury), a single dose of lithium did not significantly alter GSK-3
phosphorylation or result in significant accumulation of ß-Catenin.
Thus, while the treatment window we observed in the present
study is relatively shorter than that typically required to treat
bipolar disorder, continuous dosing was still required to signifi-
cantly alter GSK-3 activity.
The therapeutic dose for lithium is in the range of 900 mg of
lithium carbonate/day (24 mEq lithium). Usually, these patients
receive an initial dose of 300 mg (or 8mEq) to reduce the
occurrence of adverse events such as nausea and kidney injury.
The dose is then gradually increased to the recommended serum
therapeutic dose (0.6–1.2mEq/L). Although we did not monitor
the serum level of lithium, previous studies investigating its
pharmacokinetics in rats have indicated that 5 mEq/kg lithium
reaches a peak serum concentration of approximately 10 mEq/L
with a half-life of 7 hr [66]. Thus, we anticipate that 1mEq/kg
would give rise to a significantly lower serum concentration that is
more comparable to the recommended dose. In addition to
treatment of bipolar disorder with lithium alone, combined
treatment with lithium and valproic acid has been used to treat
patients resistant to monotherapy with either drug [67]. Further-
more, a combination of 60 mg/kg lithium chloride (1.4 mEq) and
300 mg/kg valproic acid delayed disease onset, reduced neuro-
logical deficits and prolonged survival in a mouse model of lateral
sclerosis as compared to either drug alone [68]. As we have
recently shown that valproic acid also offers neuroprotection and
improves cognitive function following TBI [69], future studies will
determine if a combination of lower doses of lithium (e.g.
0.25 mEq, Figure 2) and valproic acid can be used to reduce the
consequences of TBI while minimizing adverse events associated
with high doses of either drug [70,71].
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